Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a ...

Altoida’s AI-powered device to indicate Alzheimer’s in adults with mild cognitive dementia was given breakthrough designation by the FDA.

Based on new data from an ongoing trial, Eisai and Biogen's lecanemab for early Alzheimer’s was granted FDA breakthrough therapy status.

Holidays can be difficult for caregivers who have a loved one with dementia, writes columnist Ray Burow. But celebrating is still possible.

A dual vaccine targeting both amyloid plaques and tangled fibers made up of tau may have potential to treat and prevent Alzheimer’s disease.

Foralumab helped to normalize microglial cell activity - tied to Alzheimer's progression - in the mice, leading to signs of better cognition.

Potential stroke therapy 3K3A-APC, about to enter a Phase 3 trial, may also help protect the brain against Alzheimer's and other dementias.

While there is no cure for Alzheimer’s disease, nor have any disease-modifying therapies been approved yet, there are several medications available by prescription to treat disease symptoms that ...

In a significant decision, the FDA approved Adulhelm (aducanumab) as a first targeted Alzheimer's treatment, and first new therapy since 2003.

The holidays are often full of joyous anticipation, but facing dementia head-on can inspire anxiety instead, says columnist Ray Burow.

Hyperbaric oxygen therapy (HBOT) prevented the biological processes responsible for the development of Alzheimer’s disease in a mouse model.